Newsfeed

TLR3 Immune Receptor Seen As a Promising Therapeutic Target in Rat Study
Stimulating the activity of an immune system receptor called TLR3 led to a reduction of pulmonary hypertension (PH) symptoms in a rat model of the disease, making TLR3 a promising therapeutic target for treating the condition in humans. Researchers said that using treatments to restore TLR3 activity, which is reduced in patients with PH, may become a new avenue to complement existing treatment strategies.
Not so rare: The fight for rare disease treatment
Rare diseases are by definition uncommon. But, collectively, rare diseases like Gaucher, Pompe, Fabry, and MPS (mucopolysaccharidosis) affect millions of Canadians. Many of these diseases can be very serious and even life-threatening, and yet, even when an effective treatment exists, obtaining prompt and affordable access to it can be a challenge in Canada. This is something that health care experts and advocates are working to change. “In rar…
(Sorta) Supportive, a Show About Teens With Chronic Illness, Could Be Coming Your Way
A new TV comedy series will chronicle the lives of a group of teenagers with chronic illnesses, according to Deadline. “(Sorta) Supportive” will include actors with chronic illnesses or those who have family members with chronic illnesses. Travis Flores, the show’s producer and writer, has cystic fibrosis and is the recipient of a double lung transplant. Flores is also an award-winning children’s book author. Most of the cast and crew either h…
Clinical Trial Expected in 2019 to Test Therapy C76 as Potential PAH Inhibitor
A clinical trial to study a therapy that may inhibit and possibly reverse vascular remodeling in pulmonary arterial hypertension (PAH) is expected to start enrolling patients in 2019. The medicine, C76, was shown to inhibit a gene called HIF-2? and to lead to reversal of PAH in animal models. The study reporting the findings, “Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in PAH with HIF-2? Inhibitor,” was published in t…
Anti-cancer Therapy Sorafenib Reverses PAH in Rat Model, Study Reports
Treatment with the approved anti-cancer medication sorafenib reversed pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR) in a rat model, according to a new study. The findings suggest that a low-dose therapy with this compound may be successful in PAH treatment, the Japanese research team suggests.
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH).
Dave Proctor gets attention for rare diseases at Parliament Hill meeting
Ultrarunner Dave Proctor, whose attempt to break the cross-Canada speed record on foot has been halted by a back injury, met with MPs and senior policy advisers on Parliament Hill today to discuss funding for rare diseases, the cause he hit the road for in late June. Proctor, along with his family, Maureen Smith of the Canadian Organization for Rare Diseases (CORD), and Isabel and Tyler Jordan, founders of the Rare Disease Foundation, met with Co…
Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes
Fatigue and exercise intolerance are common features of pulmonary arterial hypertension (PAH), and poor exercise capacity is a predictor of worse prognosis.1 Emerging research suggests that nutritional status may have a role in the etiology and severity of these symptoms. "While patients [with PAH] have a number of risk factors for poor nutrition and nutritional deficiencies, there has been a lack of large-scale studies reporting these nutriti…
United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the Implantable System for Remodulin® (ISR). The ISR has been developed under a collaboration with Medtronic (NYSE: MDT). In December 2017, Medtronic received F…
SOX17 Gene May Contribute to PAH with Congenital Heart Disease, Study Suggests
SOX17 may be a risk gene that contributes to pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD), as well as to idiopathic and/or familial PAH, according to researchers. Their study, “Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease,” was published in the journal Genome Medicine. Current evidence indicates that CHD occurs in up to 30% of adult-onset and…
« Previous123456...43Next »
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png